Overview
Background
Matthew J. Roberts, BSc, MBBS, PhD, FRACS (Urol)
- Consultant Urologist, Royal Brisbane and Women’s (RBWH), Surgical Treatment and Rehabilitation Service (STARS), Queensland Health
- Clinician Research Fellow, Metro North Hospital and Health Service
- Group Leader & Associate Professor, The University of Queensland Centre for Clinical Research
Matthew is a medical graduate of The University of Queensland and completed Urology specialty training in Queensland and New South Wales. He completed his PhD under the supervision of Professor “Frank” Gardiner investigating new biomarkers for the early detection and characterization of prostate cancer.
Matthew is a surgeon-scientist, working clinically as a urologist and robotic surgeon at RBWH & STARS with academic appointment as Clinician Research Fellow at Metro North Health (Qld) and Associate Professor at UQCCR. His clinical and research interests are in Urologic cancers (e.g. prostate cancer), focusing on novel imaging and biomarkers, clinical trials, urological infections and innovation in urology. He has authored over 140 peer reviewed manuscripts in international journals and presented research at more than 20 international urology and clinical cancer meetings. He is a member of the EAU Prostate Cancer Guidelines Committee, Prostate Cancer Outcomes Registry (PCOR)-Queensland Steering Committee, Editorial Board of the BJU International, as well as Co-Convenor of the ANZUP 2024 ASM.
Availability
- Dr Matthew Roberts is:
- Available for supervision
Fields of research
Qualifications
- Bachelor of Biomedical Science, The University of Queensland
- Bachelor of Medicine, The University of Queensland
- Doctor of Philosophy, The University of Queensland
Research interests
-
Urology
All fields related to urology including urologic oncology, prostate cancer, kidney/renal cancer, bladder cancer and others. Urologic infections Quality-of-life and survivorship research Systematic review and meta-analysis.
Works
Search Professor Matthew Roberts’s works on UQ eSpace
2023
Journal Article
Uro-symphyseal fistula: a systematic review to inform a contemporary, evidence-based management framework
Patel, Nishal, Mehawed, Georges, Dunglison, Nigel, Esler, Rachel, Navaratnam, Anojan, Yaxley, John, Chung, Eric, Tse, Vincent and Roberts, Matthew J. (2023). Uro-symphyseal fistula: a systematic review to inform a contemporary, evidence-based management framework. Urology, 178, 1-8. doi: 10.1016/j.urology.2023.05.002
2023
Conference Publication
Dr Bot - Does AI provide quality information to prostate cancer patients?
Collin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Dr Bot - Does AI provide quality information to prostate cancer patients?. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.
2023
Journal Article
Trends and variation in prostate cancer diagnosis via transperineal biopsy in Australia and New Zealand
O' Callaghan, Michael E., Roberts, Matthew, Grummet, Jeremy, Mark, Stephen, Gilbourd, Daniel, Frydenberg, Mark, Millar, Jeremy and Papa, Nathan (2023). Trends and variation in prostate cancer diagnosis via transperineal biopsy in Australia and New Zealand. Urologic Oncology: Seminars and Original Investigations, 41 (7), 324.e13-324.e20. doi: 10.1016/j.urolonc.2023.05.011
2023
Conference Publication
Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial
Roberts, Matthew, Roberts, Natasha, Harley, Simon, Cullen, Karla, Pelecanos, Anita, Vela, Ian, Yaxley, John, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David (2023). Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.
2023
Journal Article
A novel risk calculator incorporating clinical parameters, multiparametric magnetic resonance imaging, and prostate-specific membrane antigen positron emission tomography for prostate cancer risk stratification before transperineal prostate biopsy
Kelly, Brian D., Ptasznik, Gideon, Roberts, Matthew J., Doan, Paul, Stricker, Phillip, Thompson, James, Buteau, James, Chen, Kenneth, Alghazo, Omar, O'Brien, Jonathan S., Hofman, Michael S., Frydenberg, Mark, Lawrentschuk, Nathan, Lundon, Dara, Murphy, Declan G., Emmett, Louise and Moon, Daniel (2023). A novel risk calculator incorporating clinical parameters, multiparametric magnetic resonance imaging, and prostate-specific membrane antigen positron emission tomography for prostate cancer risk stratification before transperineal prostate biopsy. European Urology Open Science, 53, 90-97. doi: 10.1016/j.euros.2023.05.002
2023
Conference Publication
Lu-PSMA Therapy - Practical considerations for urologists
Collin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Lu-PSMA Therapy - Practical considerations for urologists. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.
2023
Conference Publication
PRIMARY2 Trial Protocol: Phase III, multicentre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer
Buteau, James, Moon, Daniel, Fahey, Michael, Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Dilulio, Juliana, Lindeman, William, De Abreu, Lourenco Richard, Dhillon, Haryana M., Hofman, Michael S. and Emmett, Louise (2023). PRIMARY2 Trial Protocol: Phase III, multicentre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.
2023
Conference Publication
Can artificial intelligence devise surveillance regimens for testicular cancer?
Collin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Can artificial intelligence devise surveillance regimens for testicular cancer?. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley.
2023
Journal Article
Vitamin C as an adjunct to methenamine hippurate use after ALTAR: ego or evidence‐based?
Keogh, Kandice, Collin, Harry, Dowling, Caroline and Roberts, Matthew J. (2023). Vitamin C as an adjunct to methenamine hippurate use after ALTAR: ego or evidence‐based?. BJU International, 133 (S3), 6-7. doi: 10.1111/bju.16096
2023
Journal Article
Periurethral abscess etiology, risk factors, treatment options, and outcomes: A systematic review
Tariq, Arsalan, Stewart, Adam G., Desai, Devang J., Britton, Sumudu, Dunglison, Nigel, Esler, Rachel and Roberts, Matthew J. (2023). Periurethral abscess etiology, risk factors, treatment options, and outcomes: A systematic review. Current Urology, 17 (2), 100-108. doi: 10.1097/cu9.0000000000000159
2023
Conference Publication
Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)
Hayne, Dickon, Stockler, Martin R., Martin, Andrew James, McCombie, Steve P., Zebic, Danka Sinikovic, Bastick, Patricia A., Beardsley, Emma Kate, Frydenberg, Mark, Green, William, Grummet, Jeremy, Hawks, Cynthia, Ischia, Joseph, Mitterdorfer, Andrew, Patel, Manish, Roberts, Matthew, Sengupta, Shomik, Srivastav, Ratnesh Kumar, Redfern, Andrew David and Davis, Ian D. (2023). Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2023.41.16_suppl.TPS4617
2023
Journal Article
Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?
Roberts, Matthew J., Hruby, George, Kneebone, Andrew, Martin, Jarad M., Williams, Scott G., Frydenberg, Mark, Murphy, Declan G., Namdarian, Ben, Yaxley, John W., Hofman, Michael S., Davis, Ian D. and Emmett, Louise (2023). Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky?. BJU International, 132 (2), 146-148. doi: 10.1111/bju.16086
2023
Journal Article
Synchronous versus independent reading of PSMA‐PET and MRI to improve diagnosis for prostate cancer
Doan, Paul, Counter, William, Papa, Nathan, Sheehan‐Dare, Gemma, Ho, Bao, Lee, Jonathan, Liu, Victor, Thompson, James E., Agrawal, Shikha, Roberts, Matthew J., Buteau, James, Hofman, Michael S., Moon, Daniel, Lawrentschuk, Nathan, Murphy, Declan, Stricker, Phillip D. and Emmett, Louise (2023). Synchronous versus independent reading of PSMA‐PET and MRI to improve diagnosis for prostate cancer. BJU International, 131 (5), 588-595. doi: 10.1111/bju.15929
2023
Journal Article
Pubic symphysis septic arthritis due to urosymphyseal fistula: conservative management can work
Mehawed, Georges, Ranasinghe, Sachinka and Roberts, Matthew J. (2023). Pubic symphysis septic arthritis due to urosymphyseal fistula: conservative management can work. Urology Case Reports, 47 102356, 1-3. doi: 10.1016/j.eucr.2023.102356
2023
Conference Publication
PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer
Buteau, James Patrick, Moon, Daniel, Fahey, Michael T., Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Yeung, Theresa, Lourenco, Richard De Abreu, Dhillon, Haryana M., Hofman, Michael S. and Emmett, Louise (2023). PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. Genitourinary Cancers Symposium, Electr Network, 16-18 February 2023. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2023.41.6_suppl.TPS397
2023
Conference Publication
PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer
Buteau, James Patrick, Moon, Daniel, Fahey, Michael T., Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Yeung, Theresa, De Abreu Lourenço, Richard, Dhillon, Haryana M., Hofman, Michael S and Emmett, Louise (2023). PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps397
2023
Conference Publication
Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial
Kasivisvanathan, V., Murphy, D.G., Link, E., Lawrentschuk, N., O’Brien, J., Buteau, J.P., Roberts, M., Francis, R.J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J., Frydenberg, M., Shakher, R., Wong, L-M., Taubman, K., Lee, S.T., Hsiao, E., Nottage, M., Kirkwood, I., Iravani, A., Williams, S. and Hofman, M.S. (2023). Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial. EAU23 - 38th Annual EAU Congress, Milan, Italy, 10-13 March 2023. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0302-2838(23)01275-7
2023
Journal Article
Extracellular vesicles for precision medicine in prostate cancer: is it ready for clinical translation?
Robinson, Harley, Roberts, Matthew J., Gardiner, Robert A. and Hill, Michelle M. (2023). Extracellular vesicles for precision medicine in prostate cancer: is it ready for clinical translation?. Seminars in Cancer Biology, 89, 18-29. doi: 10.1016/j.semcancer.2023.01.003
2023
Journal Article
Variation in patient reported outcomes following radical prostatectomy: a bi-national registry-based study
O'Callaghan, Michael E., Roberts, Matthew J., Moretti, Kim L., Frydenberg, Mark, Gilbourd, Daniel, Mark, Stephen, Heathcote, Peter, Millar, Jeremy, PCOR-ANZ and Papa, Nathan (2023). Variation in patient reported outcomes following radical prostatectomy: a bi-national registry-based study. Urologic Oncology: Seminars and Original Investigations, 41 (2), 105.e9-105.e18. doi: 10.1016/j.urolonc.2022.10.020
2023
Journal Article
Plain x‐ray misses many ureteric calculi: Time to challenge the old dogma?
McGeorge, Stephen, Loh, Brendon, Shibu, Ryan, Dobeli, Karen, Brown, Nathan J., Esler, Rachel, Hacking, Craig, Purvey, Megan and Roberts, Matthew J. (2023). Plain x‐ray misses many ureteric calculi: Time to challenge the old dogma?. BJUI Compass, 4 (1), 59-61. doi: 10.1002/bco2.192
Funding
Current funding
Supervision
Availability
- Dr Matthew Roberts is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Multi-Bioanalyte Profiling of Metastatic Castration-Resistant Prostate Cancer in a Phase 2 STATEsMAN Trial
Associate Advisor
Other advisors: Associate Professor Amy McCart Reed
-
Doctor Philosophy
Roles of image fusion and 3D technology in urology: exploration and clinical integration for personalised devices
Associate Advisor
Other advisors: Professor Kristofer Thurecht
Media
Enquiries
For media enquiries about Dr Matthew Roberts's areas of expertise, story ideas and help finding experts, contact our Media team: